Celcuity EPS Ratio 2011-2025 | CELC

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Celcuity

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.83	-2.69	-2.64	-2.21	-0.92	-0.72	-0.74	-0.84	-0.52	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-0.52	-2.83	-1.57

Quarterly EPS Ratio Celcuity

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.92	-1.04	-0.86	-	-0.7	-0.62	-0.64	-	-0.83	-0.66	-0.55	-	-0.75	-0.67	-0.53	-	-0.41	-1.11	-0.25	-	-0.24	-0.21	-0.22	-	-0.19	-0.17	-0.18	-	-0.18	-0.18	-0.19	-	-0.26	-0.28	-0.15	-	-0.13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-0.13	-1.11	-0.469

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Diagnostics research industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Akumin AKU	-1.75	-	-17.87 %	$ 25.9 M	Canada
Centogene N.V. CNTG	-2.06	-	-6.23 %	$ 30.6 M	Germany
Brainsway Ltd. BWAY	-0.24	$ 19.34	0.26 %	$ 99.4 M	Israel
Burning Rock Biotech Limited BNR	-14.2	$ 20.47	-3.72 %	$ 221 M	China
Accelerate Diagnostics AXDX	-0.14	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-1.89	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	-0.72	-	0.22 %	$ 16.8 M	USA
Co-Diagnostics CODX	-1.2	$ 0.23	-5.81 %	$ 6.75 M	USA
Castle Biosciences CSTL	0.66	$ 39.52	-1.42 %	$ 1.1 B	USA
BioNano Genomics BNGO	-88.1	$ 1.52	-0.28 %	$ 1.93 M	USA
DarioHealth Corp. DRIO	1.93	$ 10.11	0.67 %	$ 287 M	Israel
DexCom DXCM	1.4	$ 67.39	-0.05 %	$ 26 B	USA
Danaher Corporation DHR	5.33	$ 229.66	-0.59 %	$ 168 B	USA
Exact Sciences Corporation EXAS	-4.67	$ 101.56	0.02 %	$ 18.8 B	USA
Enzo Biochem ENZ	-0.51	-	-8.98 %	$ 14.8 K	USA
Fulgent Genetics FLGT	-1.41	$ 26.73	-1.06 %	$ 808 M	USA
Global Cord Blood Corporation CO	4.12	-	-	$ 399 M	China
Genetic Technologies Limited GENE	-0.08	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-1.08	-	0.12 %	$ 80.1 M	China
DermTech DMTK	-3.09	-	-11.32 %	$ 2.94 M	USA
CareDx, Inc CDNA	-3.54	$ 19.42	-1.57 %	$ 1.04 B	USA
Anixa Biosciences ANIX	-0.39	$ 3.22	-5.85 %	$ 103 K	USA
Heska Corporation HSKA	-1.92	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	-24.3	-	-20.0 %	$ 1.06 M	USA
IQVIA Holdings IQV	7.57	$ 226.17	0.07 %	$ 41 B	USA
Guardant Health GH	-3.56	$ 103.5	1.09 %	$ 12.7 B	USA
Aspira Women's Health AWH	-0.23	-	-6.19 %	$ 10.5 M	USA
Illumina ILMN	-7.69	$ 134.92	-0.3 %	$ 21.5 B	USA
Charles River Laboratories International CRL	0.2	$ 202.8	-0.53 %	$ 10.4 B	USA
Myriad Genetics MYGN	-1.41	$ 6.44	-1.68 %	$ 583 M	USA
ENDRA Life Sciences NDRA	-5.55	$ 5.0	-1.96 %	$ 2.68 M	USA
Neogen Corporation NEOG	-5.03	$ 7.05	-1.33 %	$ 1.53 B	USA
National Research Corporation NRC	1.26	$ 18.65	-	$ 458 M	USA
Quest Diagnostics Incorporated DGX	7.78	$ 175.92	0.02 %	$ 19.5 B	USA
Biodesix BDSX	-0.33	$ 6.66	-2.35 %	$ 864 M	USA
Motus GI Holdings MOTS	-15.9	-	-34.28 %	$ 263 K	Israel
Laboratory Corporation of America Holdings LH	8.89	$ 253.39	-0.35 %	$ 21.3 B	USA
ICON Public Limited Company ICLR	9.6	$ 182.42	-0.69 %	$ 15 B	Irlanda
IDEXX Laboratories IDXX	10.8	$ 685.62	-0.37 %	$ 56.5 B	USA
Lantheus Holdings LNTH	4.52	$ 66.24	-0.66 %	$ 4.58 B	USA
Mettler-Toledo International MTD	40.7	$ 1 418.11	-	$ 30.1 B	Schweiz
Agilent Technologies A	3.98	$ 138.02	-0.18 %	$ 42 B	USA
Pacific Biosciences of California PACB	-1.21	$ 1.79	-5.05 %	$ 454 M	USA
Biomerica BMRA	-2.16	$ 2.7	1.89 %	$ 6.2 M	USA
Bioventus BVS	-2.49	$ 7.35	-0.41 %	$ 460 M	USA
NeoGenomics NEO	-0.62	$ 12.32	0.12 %	$ 1.56 B	USA